UnitedHealth Group Incorporated (UNH)
UnitedHealth Rises On Medicare Star Ratings Ruling; Humana Rallies
UnitedHealth rose after a federal judge ordered a rerating of the Dow Jones giant's Medicare Star Ratings. The post UnitedHealth Rises On Medicare Star Ratings Ruling; Humana Rallies appeared first on Investor's Business Daily.
UnitedHealth Group: Now A Fairly Valued Dividend-Growth Machine
UnitedHealth Group is a dividend growth stock on its way to becoming a Dividend Aristocrat. The company delivered yet another double beat in the third quarter. UnitedHealth Group's net debt to adjusted EBITDA ratio is just above 1, which supports an A+ credit rating from S&P on a stable outlook.
UnitedHealth: Navigating Policy Uncertainty Well, Solid EPS Growth Ahead
UnitedHealth Group has underperformed the broader market in 2024 but shows potential for bullish activity in 2025 despite regulatory uncertainties. UNH delivered strong Q3 results with EPS of $7.15, beating expectations, and revenue of $101 billion, driven by higher service usage. Risks include policy uncertainty and potential premium increase restrictions, but the stock remains slightly undervalued with a target price near $618.
UnitedHealth Group: Preparing For December Investor Day, Buy Reiterated
UnitedHealthcare navigates regulatory challenges, rising medical costs, and a cyberattack, maintaining growth and positioning for long-term success in a resilient healthcare sector. Despite temporary headwinds, UNH targets 13%-16% long-term earnings growth, supported by rising health expenditures and technological advancements. Optum Insight and Optum Health segments face short-term hurdles but are poised for future growth, enhancing UNH's value-based care strategy.
UnitedHealth Group Incorporated (UNH) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching UnitedHealth (UNH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CVS, UnitedHealth, Cigna sue to block FTC case over insulin prices
CVS Health, UnitedHealth Group and Cigna sued the Federal Trade Commission, claiming the agency's case against drug middlemen over high insulin prices in the U.S. is unconstitutional. The complaint is the latest move in a bitter legal fight between the three largest pharmacy benefit managers, or PBMs, in the U.S. and the FTC.
UnitedHealth Group (UNH) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, UnitedHealth Group (UNH) closed at $589.65, marking a -0.44% move from the previous day.
UnitedHealth Stock Up 12.7% YTD: Is its Premium Valuation Justified?
UNH and the broader health insurance industry will likely focus on cost-cutting initiatives and lobbying for better government reimbursement rates over time.
UnitedHealth (UNH) Up 6% Since Last Earnings Report: Can It Continue?
UnitedHealth (UNH) reported earnings 30 days ago. What's next for the stock?
The Zacks Analyst Blog UnitedHealth, Bank of America and SAP SE
UnitedHealth, Bank of America and SAP SE are included in this Analyst Blog.
DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal
The DOJ suggests that UNH's acquisitions reflect a strategy of buying competitors rather than competing directly, potentially giving it control over multiple markets.
US sues to block UnitedHealth's $3.3 bln purchase of Amedisys
The Justice Department and three U.S. states filed a lawsuit on Tuesday to block UnitedHealth Group's $3.3 billion purchase of Amedisys Inc over concern the deal would harm competition in the market for home health services, the department said.
